SCHEMBL3915034

SCHEMBL3915034

Cc1ccc(Cn2cncc(-c3ccc(O)c(F)c3)c2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.42
CYP11B2 P19099 4/20 0.42
RPS6KA3 P51812 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP17A1 P05093 1/20 0.40
CYP19A1 P11511 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.39
ACLY P53396 1/20 0.39
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
POLB P06746 1/20 0.37
TSHR P16473 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
BACE1 P56817 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911329 0.91 CYP11B1 (0.46) CYP11B1CYP11B2RPS6KA3MEN1KMT2A
SCHEMBL3112868 0.90 VEGFA (0.44) CYP11B1CYP11B2MEN1KMT2ACYP3A4
SCHEMBL3914668 0.89 ACLY (0.40) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1
SCHEMBL3920799 0.89 MEN1 (0.41) CYP11B1CYP11B2MEN1KMT2ACYP3A4
SCHEMBL3913436 0.88 HSP90AA1 (0.44) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1
SCHEMBL3913221 0.88 ESRRG (0.40) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1
SCHEMBL3913855 0.87 FNTA (0.41) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1
SCHEMBL3923792 0.87 SMN1; SMN2 (0.41) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1
SCHEMBL3924211 0.84 EGLN1 (0.51) MEN1KMT2AMAPTTHRBACLY
SCHEMBL4106346 0.82 SCD (0.44) CYP11B1CYP11B2CYP3A4CYP17A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 CYP11B1 81/4885CYP11B2 85/4885RPS6KA3 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.